TNFRSF10A and renal carcinoma: Okubo et al. also demonstrated nelfinavir-mediated potentiation of TRAIL in renal cancer cells, where the decrease in viability during combination of TRAIL and nelfinavir was reversed by the addition of DR4 and DR5 blocking antibodies.